Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment
Portfolio Pulse from
Silo Pharma has initiated an IND-enabling Good Laboratory Practice (GLP) toxicology study for SPC-15, an intranasal treatment for post-traumatic stress disorder. The study is a key milestone towards first-in-human clinical trials, following a pre-IND meeting with the FDA in September 2024. The company aims to leverage the 505(b)(2) regulatory pathway to potentially accelerate drug development and approval.
March 26, 2025 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
First dosing in GLP toxicology study represents a significant advancement for Silo Pharma's lead PTSD treatment asset, potentially bringing the company closer to first-in-human trials.
Successful initiation of IND-enabling study signals positive progression of SPC-15, potentially increasing investor confidence in the company's drug development pipeline.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100